Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

TY - JOUR

T1 - Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

AU - Snowden, John A

AU - Saccardi, Riccardo

AU - Orchard, Kim

AU - Ljungman, Per

AU - Duarte, Rafael F

AU - Labopin, Myriam

AU - McGrath, Eoin

AU - Brook, Nigel

AU - de Elvira, Carmen Ruiz

AU - Gordon, Debra

AU - Poirel, Hélène A

AU - Ayuk, Francis

AU - Beguin, Yves

AU - Bonifazi, Francesca

AU - Gratwohl, Alois

AU - Milpied, Noel

AU - Moore, John

AU - Passweg, Jakob

AU - Rizzo, J Douglas

AU - Spellman, Stephen R

AU - Sierra, Jorge

AU - Solano, Carlos

AU - Sanchez-Guijo, Fermin

AU - Worel, Nina

AU - Gusi, Andreu

AU - Adams, Gillian

AU - Balan, Theodor

AU - Baldomero, Helen

AU - Macq, Gilles

AU - Marry, Evelyne

AU - Mesnil, Florence

AU - Oldani, Elena

AU - Pearce, Rachel

AU - Perry, Julia

AU - Raus, Nicole

AU - Schanz, Urs

AU - Tran, Steven

AU - Wilcox, Leonie

AU - Basak, Grzegorz W

AU - Chabannon, Christian

AU - Corbacioglu, Selim

AU - Dolstra, Harry

AU - Kuball, Jürgen

AU - Mohty, Mohamad

AU - Lankester, Arjan

AU - Montoto, Sylvia

AU - Nagler, Arnon

AU - Styczynski, Jan

AU - Yakoub-Agha, Ibrahim

AU - de Latour, Regis Peffault

AU - Kroeger, Nicolaus

AU - Brand, Ronald

AU - de Wreede, Liesbeth C

AU - van Zwet, Erik

AU - Putter, Hein

PY - 2020/4

Y1 - 2020/4

N2 - In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.

AB - In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.

U2 - 10.1038/s41409-019-0718-7

DO - 10.1038/s41409-019-0718-7

M3 - SCORING: Review article

C2 - 31636397

VL - 55

SP - 681

EP - 694

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 4

ER -